An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease.
Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced).
In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Inclusion Criteria:
Exclusion Criteria:
Known hypersensitivity to disitamab vedotin, cisplatin, carboplatin, gemcitabine, or pembrolizumab or any of their components.
History of severe/life threatening immune-related adverse event (irAE) with PD-(L)1 inhibitors are excluded.
Central nervous system (CNS) and/or leptomeningeal metastasis. Participants with treated CNS metastases are permitted if all of the following are met.
History of or active autoimmune disease that has required systemic treatment in the past 2 years.
Prior treatment with an agent directed to another stimulatory or co-inhibitory T cell receptor (including but not limited to CD137 agonists, CAR-T cell therapy, CTLA-4 inhibitors, or OX-40 agonists).
Prior solid organ or bone marrow transplantation.
Pleural effusion or ascites with symptoms or requiring symptomatic treatment.
Estimated life expectancy <12 week
Prior treatment with an MMAE agent or anti-HER2 therapy
San Francisco, California 94115, United States
San Francisco, California 94158, United States
San Francisco, California 94158, United States
San Gabriel, California 91776, United States
Saint Louis Park, Minnesota 55426, United States
Buenos Aire, C1019ABS, Argentina
CABA, 1425, Argentina
CABA, C1430EFA, Argentina
Darlinghurst, New South Wales 2010, Australia
Macquarie University, New South Wales 2109, Australia
South Bribane, Queensland 4101, Australia
NSW, NSW 2450, Australia
Belo Horizonte, Minas Gerais 30380472, Brazil
Porto Alegre, Rio Grande do Sul 90610000, Brazil
Porto Alegre, Rio Grande do Sul 91350-200, Brazil
Oshawa, Ontario L1G 2B9, Canada
Los Condes, Region Metropolitana Santiago 7560908, Chile
Hafia, 3109601, Israel
Lombardy, Milan 20132, Italy
Florence, Tuscany 50134, Italy
Ota-Shi, Gunma 373-8550, Japan
Kita-gun, Kagawa-ken 761-0793, Japan
Hwasun-gun, Jeollanam-do 58128, South Korea
Iksan-si, Jeonlabuk-do 54538, South Korea
Badalona, Barcelona 08916, Spain
Badalona, Barcelona 08916, Spain
L'Hospitalet de Llobregat, Barcelona 08908, Spain
L'Hospitaler de Llobregat, 08908, Spain
Las Palmas de Gran Canaria, 35016, Spain
Kaoshiung, Kaohsiung 807, Taiwan
Tainan, 704017, Taiwan